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Background: Immunotherapy offers a promising novel approach for the treatment of cancer and both adoptive
T-cell transfer and immune modulation lead to regression of advanced melanoma. However, the potential synergy
between these two strategies remains unclear.
Methods: We investigated in 12 patients with advanced stage IV melanoma the effect of multiple MART-1 analog
peptide vaccinations with (n = 6) or without (n = 6) IMP321 (LAG-3Ig fusion protein) as an adjuvant in combination
with lymphodepleting chemotherapy and adoptive transfer of autologous PBMCs at day (D) 0 (Trial registration No:
NCT00324623). All patients were selected on the basis of ex vivo detectable MART-1-specific CD8 T-cell responses
and immunized at D0, 8, 15, 22, 28, 52, and 74 post-reinfusion.
Results: After immunization, a significant expansion of MART-1-specific CD8 T cells was measured in 83% (n = 5/6)
and 17% (n = 1/6) of patients from the IMP321 and control groups, respectively (P < 0.02). Compared to the control
group, the mean fold increase of MART-1-specific CD8 T cells in the IMP321 group was respectively >2-, >4- and >6-fold
higher at D15, D30 and D60 (P < 0.02). Long-lasting MART-1-specific CD8 T-cell responses were significantly
associated with IMP321 (P < 0.02). At the peak of the response, MART-1-specific CD8 T cells contained higher
proportions of effector (CCR7− CD45RA+/−) cells in the IMP321 group (P < 0.02) and showed no sign of exhaustion
(i.e. were mostly PD1−CD160−TIM3−LAG3−2B4+/−). Moreover, IMP321 was associated with a significantly reduced
expansion of regulatory T cells (P < 0.04); consistently, we observed a negative correlation between the relative
expansion of MART-1-specific CD8 T cells and of regulatory T cells. Finally, although there were no confirmed
responses as per RECIST criteria, a transient, 30-day partial response was observed in a patient from the
IMP321 group.
Conclusions: Vaccination with IMP321 as an adjuvant in combination with lymphodepleting chemotherapy and
adoptive transfer of autologous PBMCs induced more robust and durable cellular antitumor immune responses,
supporting further development of IMP321 as an adjuvant for future immunotherapeutic strategies.
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Recent advances in the understanding of the complex
cellular interactions regulating cancer immunity have led
to new strategies in the development of cancer immuno-
therapy. There is strong evidence that both adoptive T-
cell transfer and T-cell checkpoint blockade can lead to
regression of advanced melanoma [1-4]. Adoptive cell
therapy using tumor-infiltrating lymphocytes (TILs) can
mediate objective and durable tumor regressions in pa-
tients with metastatic melanoma; however, melanoma
samples cannot be obtained for TIL production from all
patients and, in some cases, TIL cannot be isolated from
the resected tumor. To overcome those potential limita-
tions, we capitalized on the adoptive transfer of periph-
eral blood mononuclear cells (PBMCs), with the
hypothesis that the vaccine would prime newly infused
T cells to mediate tumor response.
In murine models and in early clinical trials, lymphode-
pletion seemed to enhance the antitumor effects of trans-
ferred T cells in vivo by several mechanisms including the
elimination of suppressive regulatory T lymphocytes
(Tregs) [5], the elimination of cellular “sinks” for homeo-
static cytokines such as IL-7 and IL-15 [6], and the en-
gagement of toll-like receptors on antigen-presenting cells
after damage of the gut epithelium [7,8]. In these murine
models, there was a direct relationship between the extent
of lymphodepletion and the magnitude of the in vivo anti-
tumor effect of the transferred cells.
In our prior clinical trial [9,10], patients with advanced
stage III/IV melanoma received a lymphodepleting, non-
myeloablative chemotherapy consisting of Busulfan and
Fludarabine before adoptive transfer of autologous
PBMCs and MART-1 analog peptide vaccination. This
conditioning regimen induced a suboptimal lymphode-
pletion at the time of cell infusion and was associated to
a prolonged lymphopenia affecting long-term immune
reconstitution. We reported a long-lasting (over 2 years)
objective response in 1 out of 6 patients [9]. In a subse-
quent clinical phase I trial, we tested whether the use of
a different lymphodepleting regimen of Cyclophospha-
mide (CTX) at 30 mg/kg or at 60 mg/kg plus Fludarabine
at 30 mg/m2 followed by adoptive transfer of autologous
PBMCs and vaccination with MART-1peptide emulsified
in Incomplete Freund’s Adjuvant (IFA) would increase the
expansion in vivo of tumor-specific T cells and induce a
stronger anti-tumor protection [10]. We showed that
CTX plus Fludarabine was superior to Busulfan plus Flu-
darabine conditioning in terms of degree of lymphodeple-
tion, with a maximal effect obtained with a CTX dose of
60 mg/kg, and that reconstitution of T cells, particularly of
CD8 T cells, was more rapid. We reported that the depth
of homeostatic T-cell proliferation correlated tightly with
the extent of lymphodepletion and was accompanied by
increased levels of IL-15 but not of IL-7; however, despiteefficient homeostatic proliferation of total CD4 and CD8
T cells, the frequency of CD8 T cells specific for MART-1
and cancer-testis antigens were quite low. In contrast, we
observed a substantial proliferation of EBV-specific T cells;
whether this was due to homeostatic proliferation or viral
reactivation remains to be established [10].
Another question that remains so far unanswered is
whether the association of tumor-peptide vaccination
combined with a stronger adjuvant after adoptive cell
transfer would induce a more sustained anti-tumor spe-
cific CD8 T-cell expansion and potentially counterbal-
ance the homeostatic proliferation of Tregs in vivo. A
large body of work supports the idea that immunogen-
icity of a vaccine preparation is critical to induce meas-
urable antigen-specific T-cell responses in vivo. Vaccines
containing peptides mixed with IFA alone elicit only
moderate CD8 T lymphocyte-mediated responses [11].
Lymphocyte activation gene-3 (LAG-3 or CD223) pro-
tein is an important regulator of T-cell homeostasis [12].
It is a non-TLR (toll-like receptor) activator of antigen-
presenting cells (APCs) and induces dendritic cells
(DCs) migration and antigen cross-presentation to CD8
T cells. It binds to MHC class II molecules that normally
present antigenic peptides to CD4 T cells. LAG-3 is evo-
lutionarily related to CD4 and has retained an affinity of
2 logs higher than CD4 for their common ligand, MHC
II molecules on APCs such as dendritic cells. A soluble
form of the LAG-3 (sLAG-3) molecule that is derived
from an alternative splicing event can be found in hu-
man serum. In a study, breast cancer patients who had
high levels of sLAG-3 in their sera at diagnosis were
shown to have a better overall survival than patients
with low sLAG-3 levels [13].
Based on these observations, a dimeric recombinant
IMP321 molecule has been produced cGMP, consisting of
the four LAG-3 extracellular Ig-like domains fused to the
Fc fraction of a human IgG1 (LAG-3Ig). IMP321 acts as
an APC activator and is a novel adjuvant that induces po-
tent antigen-specific CD8 T-cell responses. Non-TLR ago-
nists like CD40L or LAG-3Ig are human proteins that
promote DC maturation and migration [14-17], as well as
to support the antigen-cross-presentation to a greater ex-
tent than other commonly used adjuvants [18]. In the
present study, we set out to address the question whether
the combination of lymphodepleting chemotherapy of
CTX at 30 mg/kg followed by Fludarabine at 30 mg/m2
and adoptive transfer of autologous PBMCs in association
to a MART-1 peptide vaccination with or without the
presence of the adjuvant IMP321 would elicit a more ro-
bust and long-lasting anti-tumor immunity that would fi-
nally improve patient outcome. Our study showed a more
robust and durable expansion of MART-1-specific CD8 T
cells in the IMP321 group, associated to only transient
clinical response in one patient.
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Study groups
The present trial was approved by the local IRBs and by
the Swiss national regulatory authority (Swissmedic). It
has been registered in the NCI Clinical Trials PDQ
under the number NCT00324623. Patients with stage IV
cutaneous melanoma were accrued between October
2005 and August 2011. Eligibility was based on the fol-
lowing inclusion criteria: progressive disease with no evi-
dence of brain metastases, HLA-A2 positivity; tumor
expression of Melan-A by IHC; and a measurable, en-
dogenous anti-MART-1 CD8 T-cell response for patients
that had no prior adjuvant vaccine therapy, as described
[10]. MART-1 CD8 T-cell responses were assessed by
tetramer staining using ELAGIGILTV-MHC class I mul-
timers with a threshold of 0.03% of CD8 T cells above
background. Patients underwent CT scan of the tho-
rax, abdomen, and pelvis within 4 weeks of therapy.
After collection of peripheral blood mononuclear cells
(PBMCs) by lymphocytapheresis, patients received alym-
phodepleting chemotherapy. Patients received 2 days (D-
7 and D-6) of CTX at 30 mg/kg, followed by 3 days (D-5
to D-3) of Fludarabine at 30 mg/m2. Three days later
(D0), cryopreserved PBMCs (8.9 ± 0.86×109) with a
mean 90% viability were reinfused (individual patient’s
numbers are provided in Additional file 1: Table S1), and
peptide vaccination with the MART-1 analog peptide
(MART-126–35, A27L (ELAGIGILTV), LICR Melbourne-
Austin Branch) emulsified in Incomplete Freund's Adju-
vant IFA-51 (IFA; Seppic Inc, France) was given subcuta-
neously (s.c.) at D8, 15, 22, 28, 52, and 74 post-
reinfusion as described [11,19]. IMP321 (LAG-3Ig fusion
protein, Immutep S.A., Orsay, France) was added to the
vaccine for 6 of the 12 patients, at a final concentration
of 25 μg (3 patients) and 250 μg (3 patients). Blood sam-
ples for immunomonitoring were collected before each
vaccine. G-CSF at 5 μg/kg was given s.c. starting at D1
until absolute neutrophil counts (ANC) reached > 1000
cells/μL. All patients received at least 6-month of TMP/SMX
prophylaxis and until CD4 T-cell counts were > 200 cells/μL.
Patients with positive serology for HSV at baseline re-
ceived antiviral prophylaxis with valaciclovir until re-
covery of neutropenia (ANC > 1000 cells/μL).
Synthetic peptide and peptide-MHC class I multimer complex
HPLC-purified (>80% purity) MART-1 analog peptide
(MART-126–35, A27L, ELAGIGILTV) was obtained from
LICR (Melbourn-Austin Branch) and ELAGIGILTV-
MHC class I multimers were purchased from ProIm-
mune (Oxford, UK). HLA-A2 restricted Influenza (Flu,
GILGFVFTL), Epstein-Barr Virus (EBV, GLCTLVAML)
and Cytomegalovirus (CMV, NLVPMVATV) peptides
were purchased from JPT (JPT Peptide Technologies
GmbH, Germany).Antibodies
The following Abs were used in different combinations.
CD8-PB, CD8-APCH7, CD3-APCH7, CD45RA-PECy5,
PD-1-FITC, IFN-γ-APC, TNF-α-PECy7, and IL-2-PE
were purchased from Becton Dickinson (BD, San Diego,
CA), CD4-ECD, CD3-ECD, CD28-ECD, CD27-APC
from Beckman Coulter (Fullerton, CA, USA), perforin-
FITC (clone B-D48) from Diaclone (Besançon, France),
CCR7-FITC from R&D Systems (Minneapolis, MN,
USA), 2B4-PE-Cy5.5 and CD160-APC from Biolegend
(San Diego, CA, USA) and CD127-PE-Cy7 from
eBioscience (San Diego, CA, USA).
Flow cytometer
All flow cytometry analyses from the study were per-
formed on an LSRII Becton Dickinson (BD, San Diego,
CA) SORP (4 lasers). Daily maintenance of the flow cyt-
ometer and optimal settings were determined using BD
CS&T bright bead target values for each fluorescence
detector, to obtain consistent and reproducible results
over time.
Ex vivo analysis of tumor-specific CD8 T cells
Cryo-preserved blood mononuclear cells (1-2×106) cells
were stained for dead cells (Aqua LIVE/DEAD, Invitro-
gen) and then stained with appropriately tittered
peptide-MHC class I multimer complexes at 4°C for 30’
in Ca2+-free media as described [20]. Cells were then
washed and directly stained at 4°C for 20’ with the follow-
ing Abs in various combinations: CD3, CD8, CD45RA,
CD127, CCR7, CD28, CD27, PD-1, 2B4, CD160. Finally,
cells were fixed (CellFix, BD), acquired on an LSRII SORP
and analyzed using FlowJo 8.8.2 (Tree star Inc, USA).
Analysis and presentation of distributions was performed
using SPICE version 5.1, downloaded from <http://exon.
niaid.nih.gov/spice> [21]. The number of lymphocyte-
gated events ranged between 0.6-1×106 in the flow cytom-
etry experiments.
ICS assay
Cryo-preserved blood mononuclear cells (1-2×106) were
stimulated overnight in 1ml of complete media (RPMI
(Invitrogen), 10% fetal bovine serum (FBS; Invitrogen),
100 μg/ml penicillin, 100 unit/ml streptomycin (BioCon-
cept)) in the presence of Golgiplug (1 μl/ml, BD), anti-CD28
(0.5 μg/ml, BD) and 1 μg/ml of peptide as described
[22]. Staphylococcus enterotoxin B (SEB; Sigma) stimu-
lation (100 ng/ml) served as positive control. At the end
of the stimulation period, cells were stained for dead
cells (Aqua LIVE/DEAD, Invitrogen), permeabilized
(Cytofix/Cytoperm, BD) and then stained at RT for
20’ with CD4, CD8, CD3, IFN-γ, IL-2, TNF-α and per-
forin (clone B-D48). Cells were then fixed (CellFix,
BD), acquired on an LSRII SORP and analyzed using
Table 1 Patient Demographics
IMP321 No IMP321
N (%) N (%)
Age
Median 49.5 56.8
Range 35-73 48-70
Gender
Male 3 (50%) 4 (66.6%)
Female 3 (50%) 2 (33.3%)
ECOG PS
0 4 (66.6%) 5 (83.3%)
1 2 (33.3%) 1 (16.6%)
M sub-stage
M1a 3 (50%) 1 (16.6%)
M1b 1 (16.6%) 1 (16.6%)
M1c 2 (33.3%) 4 (66.6%)
Previous therapy for Stage IV
Surgery 1 (16.6%) 2 (33.3%)
CHT or RT 2 (33.3%) 1 (16.6%)
Other 2 (33.3%) 0 (0%)
Adjuvant immunotherapy
Yes 6 (100%) 6 (100%)
No 0 (0%) 0 (0%)
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was performed using SPICE version 5.1, downloaded
from <http://exon.niaid.nih.gov/spice> [21].
IFN-γ ELISpot assay
After 7-day antigen-specific stimulation with HLA-A2+,
MART-126–35-loaded T2 cells at 1:10 APC:T cell ratio,
responder lymphocytes were tested for IFN-γ production
by ELISpot assay (1-DIK ELISpot for human IFN-γ,
Mabtech, DiaPharma Group; Vector ABC kit, Vector La-
boratories; Automated ELISpot Bioreader 5000, BIO-SYS
GmbH) according to the manufacturer’s instructions.
Targets for lymphocyte restimulation during overnight
rechallenge in the ELISpot assays were either MART-
126–35-pulsed, unpulsed T2, or HLA-A2+, MART-1+
melanoma Me205 cell lines, plated in triplicates at 30:1
effector:target (E:T) ratio. Control wells contained effec-
tors with unloaded T2 targets. Me275 is a human cell
line derived from a nodal metastasis of melanoma.
Functional avidity
Peptide stimulations were performed as described above.
Functional avidity of responses was assessed by perform-
ing limiting peptide dilutions and determining the peptide
concentration required to induce half-maximal IFN-γ re-
sponses in in vitro assays as described [23]. Peptides were
added in serial dilutions ranging from 2 μg/ml to 1 pg/ml.
EC50 was determined as the peptide concentration needed
to achieve a half-maximal response.
Statistical analysis
Unpaired and paired two-tailed student t-tests were per-
formed using Excel (Microsoft, Redmond, WA), or
GraphPad Prism version 5.03 (San Diego, CA). Correla-
tions among variables were performed by Spearman’s
test. Regarding SPICE analyses of the flow-cytometry
data, comparison of distributions was performed using
a Student's t-test and a partial permutation test as
described [21].
Results
Demographics and treatment-related toxicity
In this study, we investigated the safety of the combin-
ation of lymphodepletion and adoptive cell transfer
(ACT) of autologous PBMCs in association to a MART-
1-peptide vaccination with or without the presence of
the adjuvant IMP321 and whether it would elicit a more
robust and long-lasting anti-tumor immunity that could
ultimately improve patients outcome. Twelve HLA-A2+
patients with stage IV cutaneous melanoma and ex vivo
detectable MART-1-specific CD8 T-cell responses were
treated. Initial frequencies of circulating MART-1-
specific CD8 T cells prior to intervention were balanced
between the IMP321 and No IMP321 patient groups(Additional file 2: Figure S1A). Patients were immunized
s.c. with a MART-1 peptide at day (D) 0, 8, 15, 22, 28,
52, and 74 post-reinfusion with (n = 6) or without (n =
6) IMP321 as an adjuvant in combination with lympho-
depleting chemotherapy and adoptive transfer of autolo-
gous PBMCs. Patient gender was balanced in the
IMP321 group, as opposed to the no IMP321 group
where 66% patients were male (P = 0.6, ns). Mean age
was 54 (range, 35 to 73 years, P = 0.3, ns). ECOG per-
formance status was 0 to 1 for all patients. The majority
of patients had stage IV M1a (3 of 6 patients, 50%) and
M1c disease (4 of 6 patients, 66%) in the IMP321 and no
IMP321 group, respectively. Four patients (66.6%) had
prior chemo- or radiotherapy in the IMP321 group and
1 patient (16.6%) in control group, respectively. All pa-
tients in this study had previous adjuvant immunother-
apy (MART-1-containing anti-tumor vaccines) for their
high-risk disease. Demographic data are listed in Table 1.
As expected, hematologic toxicity was frequent in both
groups with all patients experiencing grade 3–4 leuco-
penia and CD4 T-cell lymphopenia. Febrile neutropenia
was reported in 50% of the patients in the IMP321 group
and 33% of the patients in the control group, and resolved
without clinical complications. Non-hematological toxic-
ities, as reported in Table 2, were mild.
Table 2 Treatment-related adverse events
No IMP321 N (%) IMP321 N (%) No IMP321 N (%) IMP321 N (%)
Treatment-related event
Non-hematological Grade 1-2 Grade 3-4
Fatigue 6 (100%) 6 (100%) - -
Nausea/Vomiting 5 (83%) 1 (16.6%) - -
Constipation - - 1 (16.6%) -
Alopecia 6 (100%) 6 (100%) - -
Mucositis (oral) - 1 (16.6%) - -
Weight loss 6 (100%) 6 (100%) - -
Hematological
Anemia 4 (66.6%) 5 (83%) 1 (16.6%) 1 (16.6%)
Leucopenia - - 6 (100%) 6 (100%)
Trombocitopenia - 4 (66.6%) 4 (66.6%) 2 (33%)
Febrile Neutropenia (grade 3) n/a n/a 2 (33%) 3 (50%)
CD4 Lymphopenia (≥ grade 3) n/a n/a 6 (100%) 6 (100%)
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responses following immunization in the IMP321 group
Using peptide-MHC class I multimer complexes, we moni-
tored the frequency of circulating MART-1-specific CD8 T
cells on viable CD3+ T cells in peripheral blood from pa-
tients from both groups (Figure 1A). Analyses were per-
formed at D15, D30 and D60 post-ACT and immunization
and were compared to D-15, i.e. prior to treatment. As
shown in the representative examples from Figure 1A and
B, the frequency of MART-1-specific CD8 T cells signifi-
cantly increased after immunization in the IMP321 group
but not in the control (no IMP321) group. Of note, no
dose-effect was observed at the 25 μg and 250 μg IMP321
dose levels; therefore, all patients receiving IMP321 are
pooled in the present analyses. Cumulative analyses con-
firmed a significant expansion (defined as three-fold higher
than baseline) of MART-1-specific CD8 T cells in 5 out of
6 patients (83%) from the IMP321 group compared to only
1 out of 6 patients (17%) from the control group (P < 0.02,
Figure 1C). Furthermore, compared to the control group,
the mean fold increase of MART-1-specific CD8 T cells
was respectively >2-, >4- and >6-fold higher in the IMP321
group at D15, D30 and D60. Consistently with our prior
study [10], we observed in the control arm (no IMP321) a
progressive and profound decrease in the frequency of
MART-1-specific CD8 T cells starting at D15 and still not-
able at D30 and D60 (Figure 1D). Interestingly, IMP321 ap-
pears not only to prevent this drop but also to lead to an
increase in the frequency of MART-1-specific CD8 T cells.
IMP321 immunization was therefore also associated to the
induction of a durable MART-1-specific CD8 T-cell re-
sponse at D60, which remained higher than baseline and
was significantly higher than in the control group (P < 0.02,
Figure 1D). Of note, absolute leukocyte counts andpercentages of CD4 and CD8 T-cells were comparable be-
tween the two arms (Additional file 2: Figure S1), thus indi-
cating that the aforementioned differences in the frequency
of circulating MART-1-specific CD8 T cells also reflected
absolute counts of these cells. Taken together, these obser-
vations indicate that vaccination with IMP321 was more
immunogenic and lead to a selectively stronger and more
durable anti-tumor cellular immune response.
Immunization with IMP321 induces more effector
MART-1-specific CD8 T-cell responses
We then performed qualitative analyses of MART-1-
specific CD8 T cells at the peak of response for each of the
patients from the IMP321 or control groups. We first in-
vestigated the level of T-cell differentiation of vaccine-
induced MART-1-specific CD8 T cells and analyzed the
expression of CD45RA and CCR7. MART-1-specific CD8
T cells from patients of the IMP321 groups were mostly
composed of CD45RA−CCR7− and of CD45RA+CCR7−,
i.e. two subsets of effector cells, whereas significantly higher
proportions of CD45RA+CCR7+ and CD45RA−CCR7+, i.e.
naïve and central memory cells, were observed in the con-
trol group (Figure 2A-B). These observations indicate that
vaccination with IMP321 was selectively associated with
the induction of a more effector anti-tumor immunity.
Functional potency of MART-1-specific CD8 T-cell
responses following immunization
We then comprehensively assessed the functional profile
and effector function of MART-1-specific CD8 T cells at
the peak of responses. For this purpose, cryopreserved
PBMC were thawed and stimulated with a panel of cog-
nate tumor- or viral antigens and their ability to produce
key cytokines (i.e. IFN-γ, IL-2 and/or TNF-α) and to
A 
Day-15 Day 15 Day 30 Day 60
Gated on viable CD3+CD8+  T cells
Pt#1185 
(IMP321) 
Pt#1013 
(No IMP321) 
B DC
Pt#975 (No IMP321) Pt#1257 (IMP321)
Figure 1 Kinetic of MART-1-specific CD8 T-cell responses following immunization. A. Representative example of the increase in the
frequency of circulating MART-1-specific CD8 T cells in Pt#1185 and Pt#1013 following infusion. MART-1-specific CD8 T cells are identified using
peptide-MHC class I multimer complexes and plots are gated on viable CD3+CD8+ T cells. B. Prototypic examples of the kinetic of MART-1-
specific CD8 T cells in patients from the IMP321 or no IMP321 groups. Dotted lines represent the initial frequency of MART-1-specific CD8 T cells prior
to lymphodepletion. C. Proportion of patients from each group with a peak in the frequency of MART-1-specific CD8 T cells. Peaks were defined as a
frequency of MART-1-specific CD8 T cells > three-fold higher than baseline, i.e. D-15 (n = 6 for each group, *P < 0.02). D. Cumulative analysis of the fold
increase of MART-1-specific CD8 T cells overtime in the different groups. Mean + SEM are shown (n = 6 for each group, *P < 0.02).
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polychromatic flow cytometry. Of note, the functional
profile of MART-1-specific CD8 T cells was compared to
that of an extensive set of virus-specific (i.e. Cytomegalo-
virus [CMV], Epstein Barr virus [EBV] and influenza
[Flu]) CD8 T cells. Of interest, as shown in the representa-
tive example of Pt#629 from the IMP321 group, MART-1-
specific CD8 T cells showed a level of polyfunctionality
comparable to that of CMV-specific CD8 T cells (i.e. were
mostly IFN-γ+/TNF-α+/IL-2+/−/perforin+/−; Figure 3A).
Conversely, consistently with previous studies [24,25],
EBV- and Flu-specific CD8 T cells contained a higher pro-
portion of IL-2-producing cells and showed lower perforin
expression as compared to MART-1-specific CD8 T cells
(Figure 3A). Furthermore, MART-1-specific CD8 T cells
secreted IFN-γ upon recognition of cognate Ag presented
at the cell surface of either a peptide-loaded T2 cell line
or naturally expressed by the melanoma cell line Me275
(Figure 3B). Taken together, these data demonstrate thatMART-1-specific CD8 T cells are polyfunctional and
can recognize MART-1-expressing melanoma cells.
No evidence of T-cell exhaustion of MART-1-specific CD8
T-cell responses following immunization
As a subsequent qualitative analysis, we investigated the
level of inhibitory receptor expression (“exhaustion
markers”) by vaccine-induced MART-1-specific CD8 T
cells. To this end, we analyzed the expression of PD-1,
2B4, CD160, LAG3, and TIM-3 on MART-1-specific CD8
T cells at the peak of response for each of the patients
from the IMP321 or control groups. Of interest, the ma-
jority of MART-1-specific CD8 T cells in patients from
the IMP321 or no IMP321 groups were composed of
cells lacking all the markers analyzed (i.e. were mostly
PD1−2B4−CD160−LAG3−TIM3−) or only expressed 2B4
(Figure 4A-B). However, as compared to the IMP321 group,
a significantly higher proportion of MART-1-specific CD8
T cells from the control group co-expressed PD-1 and 2B4
A B
No IMP321
(    )
IMP321
(    )
CD45RA
CC
R7
Pt#205 (IMP321) Pt#1144 (No IMP321) 
Gated on viable CD3+CD8+ T cells
%
 
o
f M
el
an
A-
sp
ec
ifi
c
CD
8 
T 
ce
lls
Figure 2 Analysis of T-cell differentiation of MART-1-specific CD8 T-cell responses following immunization. A. Representative example of
the expression of CD45RA and CCR7 on CD8 T cells in Pt#205 and Pt#1144. Total CD8 T cells appear in grey whereas blue dots represent MART-1-
specific CD8 T cells. B. Cumulative analysis of the expression of CD45RA and CCR7 on MART-1-specific CD8 T cells in patients from the IMP321 or
no IMP321 groups. All possible combinations of the distinct markers are shown on the x axis, whereas the percentages of the distinct cell subsets
within MART-1-specific CD8 T cells are shown on the y axis. The pie charts summarize the data, and each slice corresponds to a certain combin-
ation of molecules. Stars (+) indicate a significant difference using a two-tailed unpaired student t test.
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that vaccination with IMP321 does not lead to the induc-
tion of MART-1-specific CD8 T cells with a typical
exhausted phenotype.
Increase in the functional avidity of MART-1-specific CD8
T cells in patients from the IMP321 group
Functional avidity in an important feature of T-cell im-
munity [26]. We investigated whether the present ex-
perimental strategy would lead to changes in the
functional avidity of MART-1-specific CD8 T cells. For
this purpose, PBMC were stimulated with limiting dilu-
tions of MART-1 peptides and the functional avidity of
CD8 T-cell responses was assessed by determining the
peptide concentration required to induce half-maximal
IFN-γ responses (i.e. EC50). Interestingly, when we com-
pared cells isolated at baseline or 2 months after treat-
ment, we observed a significant increase in the
functional avidity of MART-1-specific CD8 T cells (P <
0.05, Additional file 3: Figure S2).
Reduced expansion of regulatory T cells following
immunization with IMP321
As mentioned above, lymphodepletion may enhance the
antitumor effects of transferred T cells by inducing the
elimination of suppressive regulatory T lymphocytes
(Tregs) [5]. We then analyzed the frequency of Tregs,
defined as CD3+CD4+CD25highFOXP3+, on live T cells in
patients from the IMP321 or control groups. We ob-
served that the frequency of Tregs was significantly
higher in the control group compared to the IMP321
group (Figure 5A and B). We then also confirmed that
the above gating strategy allowed the identification of
true regulatory T cells. As shown in Figure 5A, 80-90%
of CD3+CD4+CD25highFOXP3+ were CD45RO+CD127−,thus demonstrating that IMP321 immunization select-
ively prevented the expansion of adaptive Tregs. Of note,
absolute leukocyte counts and percentages of CD4 T-
cells were comparable between the two arms (Additional
file 2: Figure S1B and C), thus indicating that the afore-
mentioned differences in the frequency of circulating
Tregs also reflected absolute counts of these cells.
Finally, we also investigated the potential relationship
between the expansion of MART-1-specific CD8 T cells
and of Tregs in both groups. Interestingly, we observed
a significant negative correlation between the fold in-
crease of MART-1-specific CD8 T cells and that of Tregs
(Figure 5C), thus suggesting a potential mechanism for
the selective expansion of MART-1-specific CD8 T cells
in the IMP321 group.
Discussion
Current approved therapeutic options in the US and
Europe for patients with metastatic melanoma include
dacarbazine, interleukin-2, ipilimumab, vemurafenib,
dabrafenib, and trametinib, but long-term tumor regres-
sion using available agents remains out of reach for most
patients. Adoptive cell transfer (ACT) with autologous
tumor-infiltrating lymphocytes (TILs) has shown en-
couraging results in clinical trials, with evidence of dur-
able ongoing complete responses in patients with
advanced melanoma. However, melanoma samples can-
not be obtained for TIL production from all patients
and, in some cases, TILs cannot be isolated from the
resected tumor. To overcome those potential limitations,
we capitalized on the adoptive transfer of PBMCs in
combination with a MART-1 peptide vaccination sup-
plemented or not with IMP321. In this phase I study we
included a total of twelve, previously treated, advanced
melanoma patients. All the patients were HLA-A*0201
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Figure 3 CD8 T cells at peak of response secrete effector cytokines against viral and tumor Ags. A. Representative example of the ability
of CD8 T cells at peak of response to produce IFN-γ, IL-2 and/or TNF-α and to express perforin by ICS and polychromatic flow cytometry. Profiles
are gated on viable CD3+CD8+ T cells. B. PBMCs from melanoma patients at peak of response following ACT and peptide vaccination were
restimulated in vitro by T2 cells pulsed with MART-126–35 peptide. Following 1 weekly restimulation, ELISpot assays measured IFN-γ secretion
after overnight exposure to the respective peptide-loaded (≡), unloaded T2 (░), or Me205 (□) targets. Limited cell numbers precluded isolation
of CD3+CD8+ T cells for the ELISpot assays. Shown are the averaged data (means ± SEM) from 4 independent experiments each one performed
in triplicate for the number of IFN-γ spot forming cells (SFC) per triplicate of 105 input cells at 30:1 (E:T) ratio.
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reactive T cells at baseline. Age and gender were balanced
between groups, as opposed to disease stage distribu-
tion with a preponderance of subjects with worst
prognosis (66.6% vs 33.3% stage IV M1c) in the no
IMP321 group. Similar to previously reported ACT
studies, the toxicities reported in our trial were mostly
hematological and related to the lymphodepleting condi-
tioning regimen.
We set a high threshold (3-fold increase from baseline)
to define a MART-1-specific immune response, and
IMP321-supplemented vaccines stimulated significantly
greater and more sustained MART-1 tetramer reactivity
than the control group, suggesting that the addition of a
vaccine adjuvant such as the IMP321 is essential for
boosting anti-tumor immunity. No systemic dose-effectwas observed, however, at the 25 μg and 250 μg IMP321
dose levels, because such low doses were expected to
elicit local or loco-regional activation of skin APCs;
whereby, an IMP321 dose of 6 mg promoted a systemic
effect in a pharmacokinetic study in patients with ad-
vanced renal cell carcinoma [27]. Our data also show
that IMP321 is essential to prevent the decrease in
tumor-specific CD8 T cells observed without IMP321
[10]. These observations are in agreement with previous
studies, showing increased CD8 T cells and NK cell pro-
duction of Th1-effector cytokines such as IFN-γ and/or
TNF-α [28] and increased anti-tumor responses in pa-
tients with metastatic breast cancer treated with pacli-
taxel in combination with IMP321 [29]. Our data also
showed that IMP321 supported the long-term expansion
of tumor antigen-specific CD8 T cells with effector
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Figure 4 Analysis of T-cell exhaustion markers of MART-1-specific CD8 T-cell responses following immunization. A. Representative
example of the expression of 2B4, CD160, PD-1, and TIM-3 on CD8 T cells in Pt#205 and Pt#1022. Total CD8 T cells appear in grey whereas blue
dots represent MART-1-specific CD8 T cells. B. Cumulative analysis of the expression of 2B4, CD160, LAG3, PD-1, and TIM-3 on MART-1-specific
CD8 T cells in patients from the IMP321 or no IMP321 groups. All possible combinations of the distinct markers are shown on the x axis, whereas the
percentages of the distinct cell subsets within MART-1-specific CD8 T cells are shown on the y axis. The pie charts summarize the data, and each slice
corresponds to a certain combination of molecules. Stars (+) indicate a significant difference using a two-tailed unpaired student t test.
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+CCR7− cells. Antigen-experienced T cells comprise both
effector memory (TEM) and central memory (TCM), which
home respectively to inflamed tissues and lymphoid or-
gans [30]. TEM cells are associated with development of a
more robust, short-lived anti-tumor immunity [31].
Over the past decade, an overwhelming number of stud-
ies highlighted the association between the expression,
and in particular the co-expression, of co-inhibitory recep-
tors and a state of dysfunction or anergy also called ex-
haustion, as found in infectious diseases [26,32], and in
cancer [33]. These pathways are also exploited by tumors
to induce immune tolerance. In our study, we monitored
the expression of a large panel of inhibitory receptors and,
despite minor differences between groups, found no evi-
dence of co-expression of those receptors on circulating
T cells, thus indicating the lack of exhaustion of MART-1-
specific CD8 T-cell responses following immunization,
both in the IMP321 and the control arm.
Of note, functional avidity is also a relevant compo-
nent of CD8 T cells, as it reflects their sensitivity to cog-
nate antigens, i.e. how prone T cells are to respond when
they encounter low doses of antigen. It is well estab-
lished that high-avidity CD8 T-cell responses are ofhigher efficacy against cancers [34]. Several studies aimed
at increasing the avidity of anti-tumoral T cells [35,36].
Of interest, in the present study, we observed an in-
crease in the functional avidity of MART-1-specific CD8
T cells after ACT of autologous cells and immunization.
Unfortunately, our data do not allow us to establish the
influence of the multiple immunizations (as compared
to single immunization, for instance) nor the potential
contribution of IMP321. The aforementioned increase
in CD8 T-cell avidity upon immunization, however, is con-
sistent with a recent study showing increase in T-cell
avidity in HIV infection following antigen re-exposure
(virus rebound) [23].
Similar to our experience with the MART-1 vaccine,
many other cancer vaccines have also failed to induce
measurable clinical benefit, often despite the induction
of seemingly potent tumor antigen-specific Teff re-
sponses [37,38]. There are many potential explanations
for this, but one that has received particular attention in
recent years emphasizes the role of CD4+CD25+FoxP3+
Tregs. Tregs play a central role in tempering immunity
and in maintaining immune homeostasis. However, a
growing body of evidence supports the concept that
Tregs can also block the generation of effective anti-
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Figure 5 Analysis of the expansion of regulatory T cells following immunization. A. Representative examples (top panels) of the frequency
of CD25highFOXP3+ on viable CD3+CD4+ T cells in patients from the IMP321 or no IMP321 groups. Bottom panels show the expression of CD45RO and
CD127 on viable CD3+CD4+CD25highFOXP3+ regulatory T cells in a representative patient from the IMP321 group. B. Cumulative analysis of the expansion
of CD25highFOXP3+ CD4+ T in patients from the IMP321 or no IMP321 groups. The star (+) indicates a significant difference using a two-tailed unpaired
student t test. C. Correlation between the relative expansion of MART-1-specific CD8 T cells and of CD4+CD25highFOXP3+ regulatory T cells (R2 = 0.11; P < 0.05).
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CD4+CD25+Foxp3+ Tregs encompass two categories of
lymphocytes, natural and adaptive (or induced) Tregs.
Until recently, evidence for the recognition of tumor an-
tigens by Treg had been scarce, and it was unclear
whether or not Tregs would be activated and expand in
response to vaccination against tumor antigens. In re-
cent years, however, a number of reports have identified
Tregs specific for a range of tumor antigens in human
cancer, including NY-ESO-1, survivin, TRP-1, gp100,
MAGE-A3, and MART-1 [40]. Adaptive Tregs have been
shown to develop in vivo following suboptimal antigen
stimulation, in situations characterized by chronic in-
flammation, in the context of autoimmunity, allergy, and
immune responses to tumors. In our study, we observed
that the frequency of adaptive Tregs was significantly
higher in the control group, compared with the group
vaccinated with the same immunogen plus the adjuvant
IMP321 and that their frequency inversely correlated
with the expansion of MART-1-specific CD8 T cells. We
speculate that such an increased Treg frequency in the
control group may be due to the suboptimal antigenic
stimulation provided in the MART-1 plus IFA51 vaccin-
ation in immune compromised hosts, which likely lead
to a tolerogenic rather than tumor-specific response
against MART-1. On the contrary, provision of the
IMP321 to the vaccine was more immunogenic andresulted in significant increase of tetramer reactive
MART-1 CD8 T cells with an effector phenotype and a
decreased frequency of adaptive Tregs. This observation
is in line with recent findings in a melanoma mouse
model of peptide vaccination, which found that antigen-
specific Tregs were induced following subcutaneous vac-
cination with either OVA or melanoma-derived peptides,
with a restricted expansion of effector T cells. Whereas,
the addition of the more potent adjuvants CpG-ODN or
Poly (I: C) preferentially amplified effector T cells over
Tregs [41].
Although the provision of IMP321 contributed to a
significant increase of tetramer reactive MART-1 CD8 T
cells with effector properties and a decreased frequency
of adaptive Tregs, only one out of 6 patients in the
IMP321 cohort achieved a short-lived PR (Additional file
4: Figure S3) that could not be confirmed at 24-weeks
post treatment (as per RECIST criteria v1.1). One likely
explanation for the low clinical activity observed in this
study might rely on the use of non-tumor specific
PBMCs instead of TILs, as effector cells in lymphode-
pleted hosts. Several studies have demonstrated superior
anti-tumor reactivity in vitro and in vivo of TILs as com-
pared with MART-1–specific CTL lines expanded from
PBMCs [1,42,43]. In addition, lymphodepleting chemo-
therapy could have ablated antigen presenting cells,
including skin dendritic cells, countering the potential
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presentation and T-cell priming at the vaccine site, thus
hindering the clinical efficacy of our vaccination strategy.
The use of vaccines based on tumor-loaded DCs [44] or
short- plus long-peptide mix to favor helper CD4+ T-cell
responses could further improve immunogenicity and
clinical efficacy. Among the outstanding challenges, fore-
most is the need to develop ACT strategies that are
readily applicable and less labor-intensive. The recent
development of faster and optimized protocols for TILs
isolation and expansion should allow broader application
of TILs-based approaches. Emerging techniques to en-
gineer T-cell receptors (TCRs) or chimeric antigen re-
ceptors (CARs) using lymphocytes from peripheral
blood may also offer new avenues in ACT and should re-
sult in increased clinical benefit.Conclusions
The present regimen comprising multiple MART-1 vac-
cinations with or without IMP321 as an adjuvant in
combination with lymphodepleting chemotherapy and
adoptive transfer of autologous PBMCs was safe and im-
munogenic. In the arm receiving IMP321 we observed
more robust and durable cellular antitumor immune re-
sponses, therefore we encourage further development of
IMP321 for future immunotherapeutic strategies.Additional files
Additional file 1: Table S1. Absolute numbers of PBMCs collected and
infused for each patient.
Additional file 2: Figure S1. MART-1-specific CD8 T cells and T-cell
counts at baseline and post-treatment. Frequencies of MART-1-specific
CD8 T cells (A), total leukocyte counts (B), percentages of CD4 (C) and
CD8 (D) T cells are shown prior to treatment (i.e. Bsl: baseline) and/or at day
(D) 0, 15, 30, and 60 after PBMC infusion. Shown are median + interquartile
ranges in panel A and the mean ± SD in panels B-D. Patients from the
IMP321 and no IMP321 groups are shown in blue circles and red squares,
respectively.
Additional file 3: Figure S2. Analysis of the functional avidity of MART-1-
specific CD8 T cells following immunization plus IMP321. A. Representative
example of the functional avidity of MART-1-specific CD8 T cells prior to
(blue circles) and then 60 days after (red triangles) ACT and immunization.
PBMC were stimulated with decreasing concentration of MART-1 peptide
and the frequency of IFN-γ-producing CD8 T cells was determined by ICS.
The dashed line corresponds to half of the maximal response allowing the
extrapolation of the 50% effect concentration (EC50). B. Cumulative analysis
showing the significant increase in the functional avidity of MART-1-specific
CD8 T cells following immunization (n = 3).
Additional file 4: Figure S3. Short-lived partial response in a patient
from the IMP321 group. Panel A, baseline thorax-abdomen CT scan. Panel
B, thorax-abdomen CT scan 30 days after completion of study treatment.
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